Sermorelin vs GHRP-2

Sermorelin and GHRP-2 release GH through two different pituitary receptors: GHRH receptor and ghrelin receptor. Studies of the two pathways show they act synergistically when combined.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Sermorelin

Synthetic GHRH(1-29) — the shortest fully active fragment of natural growth-hormone-releasing hormone, once a registered paediatric medicine.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

🧪

GHRP-2

A synthetic hexapeptide growth-hormone-releasing peptide that acts on the ghrelin receptor and is used in some countries as a diagnostic test of GH reserve.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

SIDE BY SIDE

	Sermorelin	GHRP-2
The key difference	GHRH-receptor agonist	Ghrelin-receptor agonist
Class	GH secretagogues	GH secretagogues
Mechanism	Sermorelin is identical to the first 29 amino acids of human GHRH and stimulates GH release from the anterior pituitary through the GHRH receptor, preserving the pituitary’s own pulsatile feedback.	GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) is a ghrelin-receptor (GHS-R1a) agonist with no structural homology to GHRH.
Status	Formerly approved (Geref) for diagnosis and treatment of idiopathic GH deficiency in children; the branded product was withdrawn commercially.	Used clinically in Japan as a GH-reserve stimulation test; otherwise unapproved. Detected and banned in sport.
Reported safety signals	Clinical-era reviews reported it as well tolerated. Recent reviews flag unregulated self-administration of GH-axis peptides as a growing concern.	Diagnostic-test literature reports it as well tolerated in single-dose testing. It is not selective: secondary rises in cortisol and prolactin are documented across the GHRP class.
A key study	Reviews sermorelin as the shortest synthetic GHRH peptide with full activity, used diagnostically and therapeutically in paediatric GHD. (BioDrugs 1999, PMID 18031173)	A development profile of pralmorelin, a synthetic growth-hormone-releasing peptide developed by Polygen and Tulane University. (Drugs R D 2004, PMID 15230633)

WHEN TO RESEARCH WHICH

Sermorelin for GHRH-pathway research; GHRP-2 for ghrelin-pathway research. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Sermorelin] Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — BioDrugs 1999. PMID 18031173
[Sermorelin] PEGylation of growth hormone-releasing hormone (GRF) analogues — Adv Drug Deliv Rev 2003. PMID 14499707
[Sermorelin] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Front Endocrinol (Lausanne) 2026. PMID 42395176
[GHRP-2] Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN — Drugs R D 2004. PMID 15230633
[GHRP-2] Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder — J Endocr Soc 2022. PMID 35795807
[GHRP-2] Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry — Rapid Commun Mass Spectrom 2010. PMID 20552695

FREQUENTLY ASKED

What is the difference between Sermorelin and GHRP-2?

Sermorelin and GHRP-2 release GH through two different pituitary receptors: GHRH receptor and ghrelin receptor. Studies of the two pathways show they act synergistically when combined.

What is the regulatory status of Sermorelin and GHRP-2?

Sermorelin: Formerly approved (Geref) for diagnosis and treatment of idiopathic GH deficiency in children; the branded product was withdrawn commercially. GHRP-2: Used clinically in Japan as a GH-reserve stimulation test; otherwise unapproved. Detected and banned in sport.

What safety signals have been reported?

Sermorelin: Clinical-era reviews reported it as well tolerated. Recent reviews flag unregulated self-administration of GH-axis peptides as a growing concern. GHRP-2: Diagnostic-test literature reports it as well tolerated in single-dose testing. It is not selective: secondary rises in cortisol and prolactin are documented across the GHRP class.

Which studies is this comparison based on?

For Sermorelin: “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency” (PMID 18031173); “PEGylation of growth hormone-releasing hormone (GRF) analogues” (PMID 14499707); “The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration” (PMID 42395176). For GHRP-2: “Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN” (PMID 15230633); “Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder” (PMID 35795807); “Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry” (PMID 20552695).